Tranexamic acid for stubborn skin color darkening
Treatments studied
Part of Skin clinical trials.
This trial tests tranexamic acid to see if it improves two types of long-lasting skin pigment problems (lichen planus pigmentosus and erythema dyschromicum perstans). You may be asked to stop other pigment treatments for about a month before starting, and you’ll be screened for clotting and pregnancy-related risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a diagnosis of LPP, EDP, or AD (specific pigment skin conditions)
- You can understand the study and its risks, and you can sign consent
- You stopped all topical or oral treatments for these pigment problems (except sunscreen) at least 1 month before starting
- You do not have a history of blood clot problems (or blood clot events like DVT or stroke)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two injectable treatments for melasma (dark patches on the face): platelet-rich fibrin, which uses your own blood cells to promote healing, and tranexamic acid, a medication that may reduce pigmentation. The study will compare which works better for women with mild to moderate melasma.
This trial tests a new gel containing three active ingredients to treat melasma, a condition that causes dark patches on the skin, usually on the face. The gel is applied to the skin and may help reduce discoloration and improve skin appearance.
This trial compares two treatments for melasma, a common skin condition causing dark patches on the face. One treatment uses an injection into the affected skin (tranexamic acid), while the other uses a chemical peel (mandelic acid). The study aims to see which works better and is safer for people with darker skin tones.
This study tests whether combining oral tranexamic acid with a special skin needling treatment helps reduce melasma (dark facial patches). It is designed for women aged 18-50 who have melasma and are not pregnant or on certain medications.
This trial tests a new way to deliver a medicine (tranexamic acid) into melasma patches using ultrasound waves. It aims to see if the ultrasound helps the medicine work better to lighten the dark spots.
This trial tests a microneedling technique combined with three topical medications (metformin, tranexamic acid, and a modified Kligman's formula) to treat melasma, a common skin condition causing dark patches. The goal is to see if this approach safely and effectively reduces melasma in eligible women.
Hear when a new Lichen Planus Pigmentosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.